[HTML][HTML] Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance
Defects in apoptosis can promote tumorigenesis and impair responses of malignant B cells
to chemotherapeutics. Members of the B-cell leukemia/lymphoma-2 (BCL-2) family of …
to chemotherapeutics. Members of the B-cell leukemia/lymphoma-2 (BCL-2) family of …
The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee
Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
Plasma cell myeloma and related neoplasms
Session 1 of the 2009 Workshop of the Society for Hematopathology/European Association
of Haematopathology, Cleveland, OH, focused on plasma cell neoplasms. This report …
of Haematopathology, Cleveland, OH, focused on plasma cell neoplasms. This report …
T-lymphoblastic leukemia/lymphoma
MJ You, LJ Medeiros, ED Hsi - American journal of clinical …, 2015 - academic.oup.com
Objectives To review important concepts from the 2013 Society for Hematopathology/
European Association for Haematopathology Workshop session on T-acute lymphoblastic …
European Association for Haematopathology Workshop session on T-acute lymphoblastic …
[PDF][PDF] Genetic and functional drivers of diffuse large B cell lymphoma
Diffuse large B cell lymphoma (DLBCL) is the most common form of blood cancer and is
characterized by a striking degree of genetic and clinical heterogeneity. This heterogeneity …
characterized by a striking degree of genetic and clinical heterogeneity. This heterogeneity …
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene …
Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on …
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on …
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
ED Hsi, R Steinle, B Balasa, S Szmania… - Clinical Cancer …, 2008 - AACR
Purpose: We generated a humanized antibody, HuLuc63, which specifically targets CS1
(CCND3 subset 1, CRACC, and SLAMF7), a cell surface glycoprotein not previously …
(CCND3 subset 1, CRACC, and SLAMF7), a cell surface glycoprotein not previously …
The genetic landscape of mutations in Burkitt lymphoma
Burkitt lymphoma is characterized by deregulation of MYC, but the contribution of other
genetic mutations to the disease is largely unknown. Here, we describe the first completely …
genetic mutations to the disease is largely unknown. Here, we describe the first completely …
Genetic heterogeneity of diffuse large B-cell lymphoma
J Zhang, V Grubor, CL Love… - Proceedings of the …, 2013 - National Acad Sciences
Diffuse large B-cell lymphoma (DLBCL) is the most common form of lymphoma in adults.
The disease exhibits a striking heterogeneity in gene expression profiles and clinical …
The disease exhibits a striking heterogeneity in gene expression profiles and clinical …
[HTML][HTML] Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)
JL Rubenstein, ED Hsi, JL Johnson… - Journal of Clinical …, 2013 - ncbi.nlm.nih.gov
Purpose Concerns regarding neurocognitive toxicity of whole-brain radiotherapy (WBRT)
have motivated development of alternative, dose-intensive chemotherapeutic strategies as …
have motivated development of alternative, dose-intensive chemotherapeutic strategies as …